82745-18-4Relevant articles and documents
Compound for inhibiting SREBP-1 target point and application thereof
-
Paragraph 0067-0069, (2019/11/20)
The invention belongs to the technical field of pharmacy. Specifically, the invention provides a compound for inhibiting an SREBP-1 target, and an isomer, a pharmaceutically acceptable salt or a hydrate thereof. The invention aims to provide a compound fo
Having a spiro ring substituent of aryl morpholine compound, its preparation and use
-
Paragraph 0159-0161, (2017/08/02)
The invention discloses arylmorpholine compounds with spiro substituents. The arylmorpholine compounds are compounds having the following general formula (I), wherein X is N or CH; R1 is hydrogen, hydroxyl, alkoxy, halogen, amino, amido, acylamino, sulfam
Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases
Muth, Felix,Günther, Marcel,Bauer, Silke M.,D?ring, Eva,Fischer, Sabine,Maier, Julia,Drückes, Peter,K?ppler, Jürgen,Trappe, J?rg,Rothbauer, Ulrich,Koch, Pierre,Laufer, Stefan A.
supporting information, p. 443 - 456 (2015/07/27)
Tetra-substituted imidazoles were designed as dual inhibitors of c-Jun N-terminal kinase (JNK) 3 and p38α mitogen-activated protein (MAP) kinase. A library of 45 derivatives was prepared and evaluated in a kinase activity assay for their ability to inhibi